TickerTalks
Browse all tickers →
TickerTalks›$ZNTL
ZNZNTL

Zentalis Pharmaceuticals, Inc.

$ZNTL·$337M·Biotechnology·Healthcare
$3.56-14.2%YTD+261.5%1Y+140.5%
Mentions · last 7 days
2026-08-06: 2 posts2026-08-07: 1 posts2026-08-08: 0 posts2026-08-09: 0 posts2026-08-10: 1 posts2026-08-11: 0 posts2026-08-12: 0 posts40%
Price updated 2d ago·X counts updated 4d ago
ZNZNTL
$ZNTLZentalis Pharmaceuticals, Inc.
$3.56-14.22%4 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ZNTL, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-08-13

Catching its breath after a run — could pick back up or fade from here.

Zentalis — small-molecule oncology biotech — up 261% YTD on ESMO expectation, Q2 miss took the tape below the 50-day.

Zentalis Pharmaceuticals is a clinical-stage oncology biotech developing small-molecule therapeutics targeting validated cancer pathways. It's had a massive 12-month run (+204% TTM) on pipeline anticipation, but the Q2 print showed the operational math still requires patience.

  • The stock is up 261% YTD but Q2 EPS at -$0.59 missed consensus by 20% and the position vs 50-day just turned slightly negative (-0.7%) — that's the classic pattern of a hot-momentum name digesting a run when the underlying operational trajectory doesn't yet justify the multiple expansion.
  • Revenue remains $0 across all four quarters — the entire valuation is on pipeline optionality, primarily around the WEE1 inhibitor azenosertib and the Zn-c3 and Zn-d5 candidates targeting ovarian cancer and other oncology indications.
  • The July 17 announcement of an ESMO Congress 2026 presentation is the next material scientific catalyst — that's the venue where oncology-biotech readouts move stocks 30-50% either direction; expectations are baked in from the recent run.
  • Cash burn is running $27-35M per quarter with $337M market cap — the runway is workable but a capital raise inside 12-18 months is likely; the June 1 and Aug 3 inducement-grant announcements signal management is actively hiring, meaning the burn stays elevated.

What restarts the accelerating call: a positive ESMO Congress readout for azenosertib or Zn-c3 with clean efficacy signal — that combination sustains the momentum and takes the stock through prior highs. What confirms cooling breaks down: a negative or inconclusive ESMO readout, or an ATM-driven dilutive raise that clips the run — either would send the tape back toward $3.

What to watch: ESMO Congress 2026 (September) presentations — specifically azenosertib efficacy data and any advancing-to-Phase 3 signals. Also monitor Nov 9 Q3 earnings for cash-runway update and any capital-raise activity through the S-3 shelf.

On the calendar: 2026-11-09 — Q3 earnings

Read the AI verdict + X sentiment for $ZNTL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech developing small molecule drugs targeting fundamental cancer biology pathways across multiple solid tumor indications.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ZNTL.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ZNTL

Partial — Clinical-stage oncology biotech developing small molecule drugs targeting fundamental cancer biology pathways across multiple solid tumor indications; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-65.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-40.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-53.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.59$-0.49-20.4%
Q1 2026May 12, 2026$-0.50$-0.49-2.0%
Q4 2025Mar 26, 2026$-0.49$-0.41-19.5%
Q3 2025Nov 10, 2025$-0.37$-0.49+24.5%
Next earningsMon, Nov 9·consensus EPS $-0.61

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.50$-33.0M
Q4 FY25$0-100.0%——$-0.49$-30.9M
Q3 FY25$0———$-0.37$-27.0M
Q2 FY25$0———$-0.37$-34.7M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.1M$982K – $2.8M-$1.84-$2.11 – -$1.529
FY27$22.1M$16.1M – $25.2M-$1.63-$2.23 – -$1.087
FY28$74.4M$23.8M – $105.6M-$1.51-$2.55 – -$0.598
FY29$164.7M$75.4M – $218.2M-$0.79-$1.13 – -$0.237
FY30$285.7M$130.9M – $378.6M$0.14$0.04 – $0.207

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.4.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.41%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-17.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 48.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today9.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.895-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 6 other (6 awards) in window

See when $ZNTL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 14424B5
424B5Prospectus supplement (offering)Aug 13424B5
8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Zentalis Pharmaceuticals, Inc. reported Q2 2026 financial results and business updates for the quarter ended June 30, 2026 on August 6, 2026, signed by President and CEO Julie Eastland. In the same filing, the company began distributing an updated corporate presentation at conferences and analyst meetings under Item 7.01 Reg FD. No headline financial figures appear in the excerpt; details are in Exhibit 99.1. Routine quarterly earnings plus an investor presentation update — materiality for this clinical-stage oncology company hinges on pipeline milestones and cash runway disclosed in the press release.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Zentalis Pharmaceuticals held its 2026 Annual Meeting on June 16, 2026 with 69.47% quorum (49.45M of 71.2M eligible shares). Directors David Johnson and Jan Skvarka, Ph.D. were re-elected as Class III directors (through 2029); Ernst & Young LLP was ratified as independent auditor; and executive compensation was approved on a non-binding advisory basis. Johnson received notably lower support (20.7M for vs. 12.2M withheld). Routine annual meeting results with no governance surprises.

3New insider — initial holdingsMay 273
AI summary

Zentalis Pharmaceuticals received an initial Form 3 from Shannon Campbell, newly appointed Director (effective May 22, 2026). No common shares are reported in Table I (she has no personal stock holdings at appointment). Routine new-director Section 16(a) disclosure.

8-KOfficer or director changeMay 278-K — Item 5.02: Officer or director change
AI summary

Zentalis Pharmaceuticals appointed Shannon Campbell as a new Class I Director effective May 22, 2026, expanding the Board from 6 to 7 members. Campbell was appointed to the Compensation Committee. She will receive an annual director retainer of $45,000 per the non-employee director compensation program. This is a routine board expansion; no strategic implication stated in the filing.

8-KPress release / Reg FDMay 218-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Zentalis Pharmaceuticals announced that Phase 1b MUIR trial data for azenosertib (WEE1 inhibitor) in combination with paclitaxel in platinum-resistant ovarian cancer would be presented at the ASCO 2026 Annual Meeting (May 29 – June 2, Chicago). The MUIR trial is a multi-part open-label Phase 1b study evaluating azenosertib across four chemotherapy combinations; the paclitaxel arm was selected for ASCO presentation as paclitaxel is broadly used across tumor types. ASCO data readouts are material clinical catalysts for biotech stocks, and inclusion in ASCO suggests the data are meaningful.

8-KPress release / Reg FDMay 128-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Zentalis Pharmaceuticals announced Q1 2026 financial results (quarter ended March 31, 2026) on May 12, 2026, accompanied by a corporate investor presentation (Exhibit 99.2) being used at investor conferences. Specific financial figures are in the press release exhibit. This is a combined quarterly earnings and ongoing investor relations disclosure.

+ 15 other (3 13Gs · 3 proxys · 3 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offeringglobenewswire.com·3d agoZentalis Pharmaceuticals Announces Proposed Underwritten Public Offeringglobenewswire.com·3d agoZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updatesglobenewswire.com·10d agoZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·13d agoZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?zacks.com·27d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · last 7 days

No standout posts about $ZNTL on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport